Progesterone Receptor Negative Recruiting Phase 2 Trials for Atezolizumab (DB11595)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02849496Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced Unresectable or Metastatic Non-HER2-Positive Breast CancerTreatment
NCT02530489Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast CancerTreatment